VTL Vital Therapies, Inc.

3.75
+0  (3%)
Previous Close 3.65
Open 3.70
Price To book 2.01
Market Cap 120.54M
Shares 32,144,000
Volume 117,165
Short Ratio 57.10
Av. Daily Volume 83,803

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 VTI-208 trial failed. New VTI-308 trial initiated May 2016. Data due mid 2018.
VTI-308
Alcohol-induced liver decompensation, or AILD
Terminated September 2015 in order to reduce costs
ELAD (VTI-210)
Severe acute alcoholic hepatitis
Terminated September 2015 in order to reduce costs
ELAD (VTI-212)
Fulminant hepatic failure, or FHF, or surgery-induced acute liver failure, or SILF